17. 多系統萎縮症 Multiple system atrophy Clinical trials / Disease details

臨床試験数 : 119 / 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

diseases per page:

Showing 1 to 10 of 119 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05634876 (ClinicalTrials.gov)	April 2023	23/11/2022	UB-312 in Patients With Synucleinopathies	A Phase 1b Clinical Trial of UB-312 in Patients With Synucleinopathies	Multiple System Atrophy;Parkinson Disease	Biological: UB-312 Injection;Biological: Placebo Injection	NYU Langone Health	NULL	Not yet recruiting	40 Years	75 Years	All	8	Phase 1/Phase 2	United States
2	NCT04680065 (ClinicalTrials.gov)	April 2023	15/12/2020	GDNF Gene Therapy for Multiple System Atrophy	Randomized, Double-Blind, Placebo-controlled Safety Study of Glial Cell Line-Derived Neurotrophic Fa ...	Multiple System Atrophy	Biological: AAV2-GDNF gene therapy;Procedure: Sham (Placebo) Surgery	Brain Neurotherapy Bio, Inc.	NULL	Recruiting	35 Years	75 Years	All	9	Phase 1	United States
3	NCT05732415 (ClinicalTrials.gov)	March 1, 2023	8/2/2023	Biomarker Study of ATH434 in Participants With MSA	An Open-Label Biomarker Study of ATH434 in Multiple System Atrophy	Multiple System Atrophy	Drug: ATH434	Alterity Therapeutics	NULL	Not yet recruiting	30 Years	75 Years	All	15	Phase 2	United States
4	NCT05696717 (ClinicalTrials.gov)	March 2023	13/1/2023	Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participant ...	A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for th ...	Symptomatic Neurogenic Orthostatic Hypotension;MSA - Multiple System Atrophy	Drug: Ampreloxetine;Drug: Placebo	Theravance Biopharma	NULL	Not yet recruiting	30 Years	N/A	All	102	Phase 3	NULL
5	NCT05695378 (ClinicalTrials.gov)	February 27, 2023	22/12/2022	Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple Sy ...	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ...	Multiple System Atrophy	Drug: KM-819;Drug: Placebo	Kainos Medicine Inc.	Parexel	Recruiting	30 Years	80 Years	All	78	Phase 2	Korea, Republic of
6	NCT05486806 (ClinicalTrials.gov)	February 1, 2023	2/8/2022	Longitudinal Tracking of Patients Diagnosed With Neurodegenerative Movement Disorders	Longitudinal Tracking of Patients Diagnosed With Neurodegenerative Movement Disorders	Neurodegenerative Diseases;sca3;MSA - Multiple System Atrophy;Ataxia;Synucleinopathies	Drug: 18F-PBR06;Radiation: 18F-PBR06	Brigham and Women's Hospital	NULL	Not yet recruiting	18 Years	N/A	All	50		NULL
7	EUCTR2022-000336-28-DE (EUCTR)	12/12/2022	28/07/2022	A Study to evaluate Efficacy, Safety, Tolerability and Effects of TAK-341 in the human body in patie ...	A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tole ...	Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple s ...	Product Name: TAK-341 Product Code: TAK-341 INN or Proposed INN: Not assigned Other descriptive name: H ...	Takeda Development Center Americas, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	138	Phase 2	United Kingdom;Italy;Japan;Denmark;Austria;Germany;Portugal;France;United States;Spain
8	NCT05526391 (ClinicalTrials.gov)	November 9, 2022	1/9/2022	A Study of TAK-341 in Treatment of Multiple System Atrophy	A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tole ...	Multiple System Atrophy	Drug: TAK-341;Drug: Placebo	Takeda	AstraZeneca	Recruiting	40 Years	N/A	All	138	Phase 2	United States;Austria;Denmark;France;Germany;Italy;Japan;Portugal;Spain;United Kingdom
9	NCT05698017 (ClinicalTrials.gov)	November 7, 2022	16/1/2023	Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early- t ...	Phase 1/2a Randomized Controlled Study for Treatment of Early- to Moderate Stage Multiple System Atr ...	Multiple System Atrophy;MSA - Multiple System Atrophy	Drug: hOMSC300;Other: Sham Procedure	Cytora Ltd.	NULL	Recruiting	50 Years	80 Years	All	18	Phase 1/Phase 2	Israel
10	NCT04165486 (ClinicalTrials.gov)	July 21, 2022	14/11/2019	Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults Wi ...	A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION464 Administered Intr ...	Multiple System Atrophy	Drug: ION464;Drug: Placebo	Ionis Pharmaceuticals, Inc.	NULL	Recruiting	40 Years	70 Years	All	40	Phase 1	Austria;France;Germany;United Kingdom;Portugal

First Previous1 2 3 4 5…12Next Last